Senior Research Officers:
Dr Jake Henry
Research Assistants:
Jennifer Jackson
Helen Lenthall
Overview
The Centre for Targeted Therapy (CTT) is the Garvan Institute's centre of excellence for the development of new biological drugs. Biotechnology drugs, such as the monoclonal antibodies Pembrolizumab (Keytruda) and Adalimumab (Humira), are revolutionising the treatment of cancer and inflammatory conditions.
Technology
The Centre operates state of the art equipment required for the measurement of macromolecular interactions and for the development and characterisation of candidate drugs, including surface plasmon resonance, biolayer interferometry and bioreactor systems.
Research scope
Research at the CTT focuses on improving the transition of basic research into into drug candidates, products and treatments. The Centre is developing resources and events for the community to learn about biologics.
Current positions vacant
PhD in Antibody Therapeutics and Targeted Cancer Therapy
Director:
In the news
NHMRC awards grants to Garvan researchers - Dec 14, 2022
Genetic and molecular insights into dangerous tick bite-related meat allergy revealed - July 5, 2022
Found: a new form of DNA in our cells - April 24, 2018
Interleukin-2: releasing an immune system brake to attack tumours - July 7, 2017
